Загрузка страницы

Cepheid Receives Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B, and RSV Combination Test

Cepheid receives Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. The four-in-one test is designed for use on any of Cepheid’s over 26,000 GeneXpert® Systems placed worldwide, with results delivered in approximately 36 minutes. #Cepheid #MolecularDiagnostics

Visit www.cepheid.com/coronavirus for more information.

Видео Cepheid Receives Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B, and RSV Combination Test канала Cepheid
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
29 сентября 2020 г. 16:00:05
00:03:38
Другие видео канала
Dr. José Presa Ramos apresenta o Projeto de Erradicação da Hep CDr. José Presa Ramos apresenta o Projeto de Erradicação da Hep CXpert® Xpress GBS PCR test for Fast and Accurate Testing of Group B StrepXpert® Xpress GBS PCR test for Fast and Accurate Testing of Group B StrepCOVID-19 Challenges & Observations for Next Flu SeasonCOVID-19 Challenges & Observations for Next Flu SeasonThe Importance of a Quality Test for Managing the Spread of COVID-19The Importance of a Quality Test for Managing the Spread of COVID-19Dr. Sher M.D. FAAP Discusses Pharma Clinical Trials Utilizing Cepheid’s POC DiagnosticsDr. Sher M.D. FAAP Discusses Pharma Clinical Trials Utilizing Cepheid’s POC DiagnosticsDr. Sofia de la Villa  Discusses the diagnosis & therapeutic options for CDIDr. Sofia de la Villa Discusses the diagnosis & therapeutic options for CDIUsing Voice of Customer to Design Cepheid's GeneXpert® XpressUsing Voice of Customer to Design Cepheid's GeneXpert® XpressCepheid Partnership Promotes Access to Sexual Health Testing during European Testing WeekCepheid Partnership Promotes Access to Sexual Health Testing during European Testing WeekThe Answer is Simpler: PCR for many diseasesThe Answer is Simpler: PCR for many diseasesPaul Jr., Cepheid & American Lung Support TB Awareness in NYCPaul Jr., Cepheid & American Lung Support TB Awareness in NYCImproving Access to Community Health Testing at Berlin Stadtmission during European Testing WeekImproving Access to Community Health Testing at Berlin Stadtmission during European Testing WeekSimplicity — Dr. David Persing Discusses the PCRplus AdvantageSimplicity — Dr. David Persing Discusses the PCRplus AdvantageDr. Tim Neal Discusses Infection Control within his OrganizationsDr. Tim Neal Discusses Infection Control within his OrganizationsThe Cepheid Internship ExperienceThe Cepheid Internship ExperienceZDoggMD Discusses Tuberculosis with Cepheid CMO Dr. Dave PersingZDoggMD Discusses Tuberculosis with Cepheid CMO Dr. Dave PersingSrinath Venaktesh, India President, Danaher, Discusses the Fight Against TB in IndiaSrinath Venaktesh, India President, Danaher, Discusses the Fight Against TB in IndiaFighting Antimicrobial Resistance & Carbapenemase-producing Enterobacterales with Fast PCR TestingFighting Antimicrobial Resistance & Carbapenemase-producing Enterobacterales with Fast PCR TestingBBC StoryWorks: SCanVIR Project Enables Test & Treat for Hepatitis C Patients (French)BBC StoryWorks: SCanVIR Project Enables Test & Treat for Hepatitis C Patients (French)Dr. Bengu Discusses the Baby Cure Trial at Queen Nandi Regional Hospital Empange, South AfricaDr. Bengu Discusses the Baby Cure Trial at Queen Nandi Regional Hospital Empange, South AfricaZDoggMD Discusses the Flu with Cepheid CMO Dr. Dave PersingZDoggMD Discusses the Flu with Cepheid CMO Dr. Dave PersingDr. Gina Marrão, Leiria Hospital Center, Discusses Challenges of the Next Respiratory SeasonDr. Gina Marrão, Leiria Hospital Center, Discusses Challenges of the Next Respiratory Season
Яндекс.Метрика